With this in mind, it is possible that, if patients receive optimal adjuvant systemic therapy that is the standard of care today, the OS differences between LA HR+/HER2- BC and ES-TNBC may dissipate, but this can only be confirmed in future iterations of the NCDB that includes more patients treated in this manner. This evidence concerns the gene ERBB2 and breast cancer.